Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862251 | 0.83 | TP53 (0.67) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL4865640 | 0.83 | THRB (0.54) | MEN1KMT2ATP53THRBLMNA | |
| SCHEMBL4871956 | 0.83 | ALDH1A1 (0.67) | MEN1KMT2ATP53THRBLMNA | |
| SCHEMBL4863830 | 0.83 | TP53 (0.66) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL4865606 | 0.83 | MEN1 (0.52) | MEN1KMT2ATP53THRBLMNA | |
| SCHEMBL4869678 | 0.82 | TP53 (0.62) | MEN1KMT2ATP53THRBLMNA | |
| SCHEMBL4871110 | 0.81 | TP53 (0.59) | TP53THRBLMNAMAPTPOLB | |
| SCHEMBL4863054 | 0.81 | TP53 (0.65) | MEN1KMT2ATP53THRBLMNA | |
| SCHEMBL4868521 | 0.80 | TP53 (0.63) | TP53THRBLMNAMAPT | |
| SCHEMBL4554972 | 0.80 | MAPT (0.69) | MEN1KMT2ATP53THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | MEN1 651/4885KMT2A 2577/4885TP53 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.